Infectious and Other Complications of Immunobiologic Agents Used by HIV-Infected Individuals


Peter Chin-Hong, MD
University of California San Francisco


May 10, 2018 - 10:00 AM


May 10, 2018 - 11:15 AM


Assessment of Needs

As the HIV population ages, the risk of autoimmune diseases and malignancies is increasing. Since the late 1990s, advances in immunoregulatory cytokines or immune cells have revolutionized treatment. The pace of drug development in this area has only accelerated in recent years and a wider swath of patients with a variety of diseases are eligible for therapy. These include HIV-infected patients with rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis and an increasing number of other diseases including malignancies. When immunoregulatory molecules are targeted and blocked, infectious, and further autoimmune and malignant consequences can arise. Clinicians should be aware of specific opportunistic infections that may occur with these agents, know strategies to mitigate this risk, and devise ways to discuss risks with patients.

Learning Objectives

On completion of this webinar, learners will be able to:

  • List the types of conditions for which biologic agents may be prescribed for people with HIV infection
  • Explain the mechanism of action of these agents to a patient in your practice so that he or she may understand why certain opportunistic infections and other complications may arise
  • Describe the array of infectious and other complications that may arise with these agents
  • Design strategies that you can use in clinic to prevent infectious and other complications in your patients


Who Should Attend

This advanced webinar is designed for clinical decision makers who are actively involved in HIV care and research.

This activity is also relevant for registered nurses, PharmDs, and other health professionals.

Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.

Registration closes on Wednesday, May 9, 2018, 4:00 PM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration“at” or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credits

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.  Provider # 5-115. This program is approved for 1.25 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.

This program is approved for 1.25 hours of pharmacotherapy credit.

Pharmacy Credits

Accreditation Council for Pharmacy Education logoEducational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.25 hours (0.125 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN  # 0761-9999-18-201-L01-P

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

Gilead Sciences, Inc
ViiV Healthcare

Janssen Therapeutics

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration“at” or 415-544-9400.